Phase 1 study of galunisertib, a TGF-beta receptor i kinase inhibitor, in Japanese patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 76, Issue 6, 2015, Pages 1143-1152

  Fujiwara, Yutaka ^a   Nokihara, Hiroshi ^a   Yamada, Yasuhide ^a   Yamamoto, Noboru ^a   Sunami, Kuniko ^a   Utsumi, Hirofumi ^a,e   Asou, Hiroya ^b   Takahashi, Osamu ^b   Ogasawara, Ken ^c   Gueorguieva, Ivelina ^d   Tamura, Tomohide ^a,f  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b Medical Science Lilly Research Laboratories Development Center of Excellence Japan Eli Lilly Japan KK   (Japan)

^c Eli Lilly Japan KK   (Japan)

^d ELI LILLY AND COMPANY   (United States)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

Author keywords

Galunisertib; LY2157299; Pharmacokinetics; Safety; TGF beta

Indexed keywords

ALKALINE PHOSPHATASE; BRAIN NATRIURETIC PEPTIDE; GALUNISERTIB; TRIACYLGLYCEROL LIPASE; LY-2157299; PROTEIN SERINE THREONINE KINASE; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BILIARY TRACT INFECTION; CANCER PATIENT; CARDIOTOXICITY; CLINICAL ARTICLE; CONSTIPATION; DECREASED APPETITE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM ULCER; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ELIMINATION HALF-LIFE; EVENING DOSAGE; FEMALE; FEVER; HUMAN; HYPOPHOSPHATEMIA; INTESTINAL BLEEDING; JAPANESE (PEOPLE); LEUKOPENIA; LUNG CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MONOTHERAPY; MORNING DOSAGE; OPEN STUDY; PANCREAS CANCER; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; SEPSIS; SOLID TUMOR; THORAX RADIOGRAPHY; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DOPPLER IMAGING; VOLUME OF DISTRIBUTION; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; ETHNOLOGY; INSOMNIA; JAPAN; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CONSTIPATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXANTHEMA; FEMALE; HUMANS; JAPAN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; QUINOLINES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 84947571118     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2895-4     Document Type: Article

References (26)

1. Massague J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103:295-309. doi: 10.1016/S0092-8674(00)00121-5
2. Pasche B (2001) Role of transforming growth factor beta in cancer. J Cell Physiol 186:153-168. doi: 10.1002/1097-4652(200002)186:2<153:AID-JCP1016>3.0.CO;2-J
3. Akhurst RJ, Hata A (2012) Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov 11:790-811. doi: 10.1038/nrd3810
4. Massague J (1998) TGF-beta signal transduction. Annu Rev Biochem 67:753-791. doi: 10.1146/annurev.biochem.67.1.753
5. Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB (1981) New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci USA 78:5339-5343
6. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH (1986) Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83:4167-4171
7. Zavadil J, Bottinger EP (2005) TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24:5764-5774. doi: 10.1038/sj.onc.1208927
8. Bhola NE, Balko JM, Dugger TC, Kuba MG, Sanchez V, Sanders M, Stanford J, Cook RS, Arteaga CL (2013) TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Investig 123:1348-1358. doi: 10.1172/JCI65416
9. Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, Trocóniz IF (2008) Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer 44:142-150. doi: 10.1016/j.ejca.2007.10.008
10. Dituri F, Mazzocca A, Peidro FJ, Papappicco P, Fabregat I, De Santis F, Paradiso A, Sabbà C, Giannelli G (2013) Differential inhibition of the TGF-beta signaling pathway in HCC cells using the small molecule inhibitor LY2157299 and the D10 monoclonal antibody against TGF-beta receptor type II. PLoS ONE 8:e67109. doi: 10.1371/journal.pone.0067109
11. Giannelli G, Villa E, Lahn M (2014) Transforming growth factor-beta as a therapeutic target in hepatocellular carcinoma. Cancer Res 74:1890-1894. doi: 10.1158/0008-5472.CAN-14-0243
12. Lahn M, Kloeker S, Berry BS (2005) TGF-beta inhibitors for the treatment of cancer. Expert Opin Investig Drugs 14:629-643. doi: 10.1517/13543784.14.6.629
13. Maier A, Peille AL, Vuaroqueaux V, Lahn M (2015) Anti-tumor activity of the TGF-beta receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts. Cell Oncol 38:131-144. doi: 10.1007/s13402-014-0210-8
14. Leivonen SK, Kahari VM (2007) Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer 121:2119-2124. doi: 10.1002/ijc.23113
15. Sawyer JS, Anderson BD, Beight DW, Campbell RM, Jones ML, Herron DK, Lampe JW, McCowan JR, McMillen WT, Mort N, Parsons S, Smith EC, Vieth M, Weir LC, Yan L, Zhang F, Yingling JM (2003) Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J Med Chem 46:3953-3956. doi: 10.1021/jm0205705
16. Rodon J, Carducci MA, Sepulveda-Sanchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly AL, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J (2014) First-in-human dose study of the novel transforming growth factor-beta receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-14-1380
17. Faivre SJ, Santoro A, Kelley RK, Merle P, Gane E, Douillard J-Y, Waldschmidt D, Mulcahy MF, Costentin C, Minguez B, Papappicco P, Gueorguieva I, Cleverly A, Desaiah D, Lahn MM, Ameryckx S, Benhadji KA, Raymond E, Giannelli G (2014) A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC). ASCO Gastrointestinal Cancers Symposium: J Clin Oncol 32:suppl 3; abstract LBA173
18. Anderton MJ, Mellor HR, Bell A, Sadler C, Pass M, Powell S, Steele SJ, Roberts RR, Heier A (2011) Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol Pathol 39:916-924. doi: 10.1177/0192623311416259
19. First in human dose escalation study of TEW-7197 in subjects with advanced stage solid tumors. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02160106?term=TEW7197&rank=1. Accessed 22 March 2015
20. Stauber AJ, Credille KM, Truex LL, Ehlhardt WJ, Young JK (2014) Nonclinical safety evaluation of a transforming growth factor b receptor I kinase inhibitor in Fischer 344 rats and beagle dogs. J Clin Toxicol. doi: 10.4172/2161-0495.196
21. Kovacs RJ, Maldonado G, Azaro A, Fernandez MS, Romero FL, Sepulveda-Sanchez JM, Corretti M, Carducci M, Dolan M, Gueorguieva I, Cleverly AL, Pillay NS, Baselga J, Lahn MM (2014) Cardiac safety of TGF-beta receptor I kinase inhibitor LY2157299 monohydrate in cancer patients in a first-in-human dose study. Cardiovasc Toxicol. doi: 10.1007/s12012-014-9297-4
22. Gueorguieva I, Cleverly AL, Stauber A, Sada Pillay N, Rodon JA, Miles CP, Yingling JM, Lahn MM (2014) Defining a therapeutic window for the novel TGF-beta inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. Br J Clin Pharmacol 77:796-807. doi: 10.1111/bcp.12256
23. Kozloff M, Carbonero R, Nadal T, Gueorguieva I, Cleverly A, Desaiah D, Lahn MMF, Pillay S, Blunt A, Josep Tabernero, Macarulla T (2013) Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ss) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in patients with advanced cancer. ASCO Meet Abstr 31:2563
24. Suarez C, Rodon J, Desjardins A, Forsyth PAJ, Gueorguieva I, Cleverly A, Burkholder T, Desaiah D, Lahn MMF, Wick W (2013) Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ss) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with chemoradiotherapy in newly diagnosed malignant gliomas. ASCO Meet Abst 31:2039
25. A study of LY2157299 in participants with myelodysplastic syndromes. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/results/NCT02008318. Accessed 26 Feb 2015
26. Rodon J, Carducci M, Sepulveda-Sanchez JM, Azaro A, Calvo E, Seoane J, Brana I, Sicart E, Gueorguieva I, Cleverly A, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J (2015) Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-beta receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Investig New Drugs 33:357-370. doi: 10.1007/s10637-014-0192-4